Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US

BACKGROUND AND AIMS: Coronavirus disease 2019 (COVID-19) imposes a substantial and ongoing burden on the US healthcare system and society. Molnupiravir is a new oral antiviral for treating COVID-19 in outpatient settings. This study evaluated the cost-effectiveness profile of molnupiravir versus bes...

Descripción completa

Detalles Bibliográficos
Autores principales: Goswami, Hardik, Alsumali, Adnan, Jiang, Yiling, Schindler, Matthias, Duke, Elizabeth R., Cohen, Joshua, Briggs, Andrew, Puenpatom, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270266/
https://www.ncbi.nlm.nih.gov/pubmed/35779197
http://dx.doi.org/10.1007/s40273-022-01168-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270266/
https://www.ncbi.nlm.nih.gov/pubmed/35779197
http://dx.doi.org/10.1007/s40273-022-01168-0

Ejemplares similares